Key facts
- This page summarizes Robert Dee Etherington's Form 4 filing for Clene Inc. (CLNN).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 10 Jun 2024, 16:17.
Robert Dee Etherington - 07 Jun 2024 Form 4 Insider Report for Clene Inc. (CLNN)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- CLNN
- Reported as of
- 07 Jun 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 10 Jun 2024, 16:17:06 UTC
- Prior SEC filing
- 03 Jul 2023
- Next SEC filing
- 30 Jul 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jerry Miraglia POA
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Robert Dee Etherington filed Form 4 for Clene Inc. (CLNN) on 10 Jun 2024.
Change
- Previous filing in this sequence was filed on 03 Jul 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CLNN
transaction
Derivative
Stock Options (Right to buy)
Award
- Transaction value
- $0
- Shares
- +900,000
- Change %
- Price
- $0.000000
- Shares after
- 900,000
- Date
- 07 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 900,000
- Exercise price
- $0.3700
- Footnotes
- F1
CLNN
transaction
Derivative
Stock Options (Right to buy)
Award
- Transaction value
- $0
- Shares
- +2,250,000
- Change %
- Price
- $0.000000
- Shares after
- 2,250,000
- Date
- 07 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,250,000
- Exercise price
- $0.3700
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
This option was granted on June 7, 2024 as an option for 900,000 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $0.37 per share. The options vest with respect to the first 25% of such shares on June 7, 2025 and then in 36 equal installments of Common Stock on the 7th day of each calendar month, beginning July 7, 2025, until such shares are fully vested
Footnote F2
This option was granted on June 7, 2024 as an option for 2,250,000 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $0.37 per share. The options vest with respect to the first 33.3% of such shares if Clene Inc. has an NDA accepted by the FDA, an additional 33.3% of such shares if Clene Inc. has an NDA approved by the FDA, and the remaining 33.4% of such shares if Clene Inc. achieves $100,000,000 in revenues in connection with the sales of any approved drugs.